

IN TH	E UNITED STATES PATENT AND TRADEMARK OFFICE
In re application of: Serial No.: Filing Date: For: Docket No.	Wagle, et al. 10/036,857  December 31, 2001  "Method for Treating Fibrotic Diseases or Other Indications III C" 361331-512
Commissioner for Pa Washington, DC 202	
the United States Po	t this correspondence is being deposited with sufficient postage with ostal Service as first-class mail in an envelope addressed to: Patents, Washington, D.C. 20231, on April 9, 2003.  By: Levile Cliver
	IATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56
Appliche documents:	cants herein make available to the Patent and Trademark Office copies of
<b>♂</b>	listed on enclosed Form PTO/SB/08A/B (Formerly PTO-1449), in accordance with 37 CFR 1.98(a)(2); and
	listed on enclosed copies of Forms PTO-1449, PTO-892 or PTO/SB/08A/B, which forms recited the application information for applications to which this application claims priority under 35 U.S.C. §120, but have been edited to indicate the current application data. Pursuant to 37 CFR 1.98(d), NO COPIES OF THESE DOCUMENTS ARE ENCLOSED. The prior applications that provide the source of these documents are:
	Serial No, filed;

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

Serial No. \_\_\_\_\_\_, filed \_\_\_\_\_;

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

Under 37 CFR 1.97(i), Applicants understand that non-complying Information Disclosure Statements will be placed in the file but not considered by the Office, however, under Reply to Comment 8 of the Federal Register, page 2024, Applicants will be informed when information is not considered.

(1)	This Inf	forma	tion Disclosure Statement is being filed (one of a - e):	
	(a)		within three months of the filing date of the patent application.	
	(b)		within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.	
	(c)	$\boxtimes$	before the mailing date of a first Office Action on the merits.	
	(d)		after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by:	
			the Statement under 37 CFR 1.97(e) (see "Statement" below);	
			or .	
			the Fee of \$180.00 set forth in 37 CFR 1.17(p); or	
	(e)		after the period set forth above in (d) and after mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by:	
			the Statement under 37 CFR 1.97(e) (see "Statement" below);	
			and	
			the Fee of \$180.00 set forth in 37 CFR 1.17(p); or	
(2)	Stateme	ent		
		The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.		


(If this box is checked, do not check any further Statement boxes.)

	<b>~-</b>
	The person signing immediately below hereby states that no item of information contained in the Information Disclosure was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.
The pers	son making the statement is:
	the inventor(s) who sign(s) below:
	Signature of the Inventor(s)
	Typed or Printed Name of the Inventor(s)
	or
	a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below:
	Signature of the Person(s)
	Typed or Printed Name of the Person
	Address of Person Signing
	or
	the undersigned attorney who signs on the basis of the information:
	supplied by the inventor(s).
	supplied by an individual designated in 37 CFR 1.56(c).
	in the attorney's file.
5	Signature of the Attorney

(3)	Fees					
	$\boxtimes$	No Fee is owed by the applicants.				
		The IDS Fee of \$180.00 under 37 CFR 1.17(p) is enclosed herewith.				
(4)	Method	of Payment of Fees				
		Attached is a check in the amount of \$				
		Charge Account No. 04-0480 in the amount of \$00. (A duplicate of this request is attached).				
(5)	Authorization to Charge Additional Fees					
	$\boxtimes$	If any additional fees are owed in connection with this communication, please charge Deposit Account No. 04-0480.				
(6)	Instruct	tions as to Overpayment				
		Please credit Account No. 04-0480 for any overpayment.				
		Please refund Dechert LLP in the amount of \$				
	Conside	ration of the Information Disclosure Statement is earnestly solicited.				
		Respectfully submitted,				
		at E Jackson				
		Arthur E. Jackson  Registration No. 34,354				
		105101111111111111111111111111111111111				

DECHERT LLP
Princeton Pike Corporate Center
PO Box 5218
Princeton, New Jersey 08543-5218
Fax: (609) 620-3259

Attn: Arthur E. Jackson (609 620-3254)



## RECEIVED

APR 1 5 2003

TECH CENTED 400 Sheet 1 of 1

Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No. 361331-512 Serial No.: 10/036,857 Applicant: Wagle, et al.

Information Disclosure
Statement by Applicant

Filing Date: December 31, 2001

(use several Sheets if necessary)

Group No. 1614

## **U.S. PATENT DOCUMENTS**

Exmr Initial		Patent Number	Issue Date	Patentee	Class	Sub- Class	Filing Date  If Appropriate
	A1	5,656,261	08/12/97	Cerami, et al.	424	53	
	A2	5,853,703	12/29/98	Cerami, et al.	424	53	
	A3	6,007,865	12/28/99	Cerami, et al.	426	656	
	A4	6,121,300	09/19/00	Wagle, et al.	514	365	
	A5	6,462,057	10/08/02	Sankaranarayanan	514	336	
	A6	2003/0008817	01/09/03	Sander, et al.	514	12	
	Α7	2003/0045554	03/06/03	Sankaranarayanan	514	340	
	•	FOREIGN PATE	NT OR PUB	LISHED FOREIGN PAT	ENT APP	LICATION	
Exmr		Document Number	Publn Date*	Country or Patent	Class	Sub-	Translation? Yes No

Exmr Initial		Document Number	Publn Date*	Country or Patent Office	Class	Sub- Class	Translation? Yes No
	A8	WO 01/25208 A1	04/12/01	PCT			
:							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Place of Publication\*\*)

1 1	
Examiner	Date Considered

149231.1.07

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO - 2)

Use publication date indicated on the patent or published application. 37 CFR 1.98(b).

<sup>\*\*</sup> The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.